| Record Information | 
|---|
| Version | 5.0 | 
|---|
| Status | Detected but not Quantified | 
|---|
| Creation Date | 2012-09-06 15:16:49 UTC | 
|---|
| Update Date | 2022-03-07 02:51:35 UTC | 
|---|
| HMDB ID | HMDB0014352 | 
|---|
| Secondary Accession Numbers | - HMDB0001916
 
- HMDB01916
 
- HMDB14352
 
  | 
|---|
| Metabolite Identification | 
|---|
| Common Name | Azithromycin | 
|---|
| Description | Azithromycin is a semi-synthetic macrolide antibiotic of the azalide class. It is used to treat certain bacterial infections, most often bacteria causing middle ear infections, tonsillitis, throat infections, laryngitis, bronchitis, pneumonia, and sinusitis. It is also effective against certain sexually transmitted infectious diseases, such as non-gonococcal urethritis and cervicitis. Like other macrolide antibiotics, azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit of the bacterial 70S ribosome. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the process of translation. Its effects may be bacteriostatic or bactericidal depending of the organism and the drug concentration. Its long half-life, which enables once-daily dosing, and shorter administration durations is a property distinct from other macrolides. Azithromycin is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring, thus making the lactone ring 15-membered. Azithromycin is sold under the brand names Zithromax ("Zmax") and Sumamed, and is one of the world's best-selling antibiotics. | 
|---|
| Structure | CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1  | 
|---|
| Synonyms | | Value | Source | 
|---|
 | (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one | ChEBI |  | Azenil | ChEBI |  | Azifast | ChEBI |  | Azigram | ChEBI |  | Azimakrol | ChEBI |  | Azithromycine | ChEBI |  | Azithromycinum | ChEBI |  | Azitromicina | ChEBI |  | Azitromin | ChEBI |  | Hemomycin | ChEBI |  | Zithromax | ChEBI |  | Zmax | ChEBI |  | (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one | Generator |  | (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one | Generator |  | Azithramycine | HMDB |  | Azithromycin dihydrate | HMDB |  | Azythromycin | HMDB |  | Dihydrate, azithromycin | HMDB |  | Monohydrate, azithromycin | HMDB |  | Pfizer brand OF azithromycin | HMDB |  | Azadose | HMDB |  | Azitrocin | HMDB |  | Funk brand OF azithromycin dihydrate | HMDB |  | Pharmacia brand OF azithromycin dihydrate | HMDB |  | Sumamed | HMDB |  | Zentavion | HMDB |  | Azithromycin monohydrate | HMDB |  | Azithromycin pfizer brand | HMDB |  | Goxal | HMDB |  | Mack brand OF azithromycin dihydrate | HMDB |  | Toraseptol | HMDB |  | Bayer brand OF azithromycin dihydrate | HMDB |  | Lesvi brand OF azithromycin dihydrate | HMDB |  | Pfizer brand OF azithromycin dihydrate | HMDB |  | Ultreon | HMDB |  | Vinzam | HMDB |  | Vita brand OF azithromycin dihydrate | HMDB |  | Zitromax | HMDB |  
  | 
|---|
| Chemical Formula | C38H72N2O12 | 
|---|
| Average Molecular Weight | 748.9845 | 
|---|
| Monoisotopic Molecular Weight | 748.508525778 | 
|---|
| IUPAC Name | (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-2-ethyl-3,4,10-trihydroxy-13-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one | 
|---|
| Traditional Name | azithromycin | 
|---|
| CAS Registry Number | 83905-01-5 | 
|---|
| SMILES | CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O  | 
|---|
| InChI Identifier | InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1  | 
|---|
| InChI Key | MQTOSJVFKKJCRP-BICOPXKESA-N | 
|---|
| Chemical Taxonomy | 
|---|
| Description |  Belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars. | 
|---|
| Kingdom | Organic compounds   | 
|---|
| Super Class | Organic oxygen compounds   | 
|---|
| Class | Organooxygen compounds   | 
|---|
| Sub Class | Carbohydrates and carbohydrate conjugates   | 
|---|
| Direct Parent | Aminoglycosides   | 
|---|
| Alternative Parents |  | 
|---|
| Substituents | - Aminoglycoside core
 
- Macrolide
 
- Glycosyl compound
 
- O-glycosyl compound
 
- Monosaccharide
 
- Oxane
 
- Tertiary alcohol
 
- 1,2-aminoalcohol
 
- Amino acid or derivatives
 
- Carboxylic acid ester
 
- Lactone
 
- Secondary alcohol
 
- Tertiary amine
 
- Tertiary aliphatic amine
 
- Oxacycle
 
- Acetal
 
- Monocarboxylic acid or derivatives
 
- Organoheterocyclic compound
 
- Polyol
 
- Azacycle
 
- Ether
 
- Dialkyl ether
 
- Carboxylic acid derivative
 
- Organic nitrogen compound
 
- Alcohol
 
- Carbonyl group
 
- Organonitrogen compound
 
- Organopnictogen compound
 
- Amine
 
- Organic oxide
 
- Hydrocarbon derivative
 
- Aliphatic heteromonocyclic compound
 
  | 
|---|
| Molecular Framework | Aliphatic heteromonocyclic compounds | 
|---|
| External Descriptors |  | 
|---|
| Ontology | 
|---|
| Physiological effect | Not Available | 
|---|
| Disposition |  | 
|---|
| Process |  | 
|---|
| Role |  | 
|---|
| Physical Properties | 
|---|
| State | Solid | 
|---|
| Experimental Molecular Properties | | Property | Value | Reference | 
|---|
 | Melting Point | 113 - 115 °C | Not Available |  | Boiling Point | Not Available | Not Available |  | Water Solubility | 0.51 g/L | Not Available |  | LogP | 4.02 | MCFARLAND,JW ET AL. (1997) |  
  | 
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections | 
|---|
| Predicted Molecular Properties |  | 
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference | 
|---|
 | Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter)). Predicted by Afia on May 17, 2022. | 3.62 minutes | 32390414   |  | Predicted by Siyang on May 30, 2022 | 11.8197 minutes | 33406817   |  | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.32 minutes | 32390414   |  | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 360.0 seconds | 40023050   |  | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1177.9 seconds | 40023050   |  | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 141.3 seconds | 40023050   |  | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 178.6 seconds | 40023050   |  | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 178.5 seconds | 40023050   |  | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 98.5 seconds | 40023050   |  | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 433.4 seconds | 40023050   |  | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 418.0 seconds | 40023050   |  | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 861.2 seconds | 40023050   |  | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 824.9 seconds | 40023050   |  | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 184.9 seconds | 40023050   |  | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 700.4 seconds | 40023050   |  | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 247.0 seconds | 40023050   |  | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 312.4 seconds | 40023050   |  | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 256.7 seconds | 40023050   |  | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 695.4 seconds | 40023050   |  | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 12.7 seconds | 40023050   |  
 Predicted Kovats Retention IndicesUnderivatized | 
|---|